Joseph Klein III - Jul 15, 2021 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Joseph Klein III
Stock symbol
IONS
Transactions as of
Jul 15, 2021
Transactions value $
-$152,989
Form type
4
Date filed
7/19/2021, 08:14 PM
Previous filing
Jul 6, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $0 +5.33K +38.66% $0.00 19.1K Jul 15, 2021 Direct F1
transaction IONS Common Stock Options Exercise $0 +889 +4.65% $0.00 20K Jul 15, 2021 Direct F1
transaction IONS Common Stock Options Exercise $0 +666 +3.33% $0.00 20.7K Jul 15, 2021 Direct F1
transaction IONS Common Stock Options Exercise $0 +1.78K +8.6% $0.00 22.5K Jul 15, 2021 Direct F1
transaction IONS Common Stock Sale -$153K -4.33K -19.3% $35.30 18.1K Jul 15, 2021 Direct F2, F3
holding IONS Common Stock 100 Jul 15, 2021 by Son F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Restricted Stock Unit Options Exercise $0 -5.33K -28.92% $0.00 13.1K Jul 15, 2021 Common Stock 5.33K $0.00 Direct F5, F6
transaction IONS Restricted Stock Unit Options Exercise $0 -889 -6.78% $0.00 12.2K Jul 15, 2021 Common Stock 889 $0.00 Direct F5, F7
transaction IONS Restricted Stock Unit Options Exercise $0 -666 -5.45% $0.00 11.6K Jul 15, 2021 Common Stock 666 $0.00 Direct F5, F7
transaction IONS Restricted Stock Unit Options Exercise $0 -1.78K -15.39% $0.00 9.78K Jul 15, 2021 Common Stock 1.78K $0.00 Direct F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.
F2 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.78 to $35.68 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4 The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F5 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F6 Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.
F7 Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.